Shaanxi Panlong Pharmaceutical Group Limited By Share Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Xiaolin Xie

Algemeen directeur

CN¥386.8k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	35.4%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.4yrs

Recente managementupdates

Recent updates

There Is A Reason Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) Price Is Undemanding

Sep 30

Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Shareholders Will Receive A Bigger Dividend Than Last Year

May 31

We Think That There Are Some Issues For Shaanxi Panlong Pharmaceutical Group Limited By Share (SZSE:002864) Beyond Its Promising Earnings

May 02

Earnings Not Telling The Story For Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) After Shares Rise 32%

Mar 06

CEO

Xiaolin Xie (56 yo)

no data

Tenure

CN¥386,800

Compensatie

Mr. Xiaolin Xie is General Manager & Chairman of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Xiaolin Xie	GM & Chairman	no data	CN¥386.80k	35.37% CN¥ 1.0b
Dezhu Zhang	Deputy & GM Director	1.4yrs	CN¥153.90k	0.11% CN¥ 3.1m
Zhihong Zhang	Deputy GM & Director	no data	CN¥126.00k	1.07% CN¥ 30.5m
Jie Wu	Deputy GM	no data	CN¥168.00k	0.64% CN¥ 18.3m
Qingshui Luo	Chairman of the Supervisory Board & Director of Legal Department	no data	geen gegevens	0.19% CN¥ 5.4m
Xiaofeng Xie	Non-Independent Director	11.4yrs	geen gegevens	0.70% CN¥ 19.9m
Wenfeng Zhu	Shareholder Supervisor	2.2yrs	CN¥137.20k	0.086% CN¥ 2.4m
Haiyun Ren	Independent Director	5.2yrs	CN¥80.00k	geen gegevens
Leipeng Jiao	Independent Director	5.2yrs	CN¥80.00k	geen gegevens
Hui Ma	Shareholder Supervisor	2.2yrs	geen gegevens	0.019% CN¥ 541.6k
Zhekun Chen	Supervisor	no data	geen gegevens	0.0019% CN¥ 54.1k
Xiaofeng Niu	Independent Director	2.4yrs	CN¥80.00k	geen gegevens

2.4yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002864 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.

Shaanxi Panlong Pharmaceutical Group Limited By Share Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd, Annual General Meeting, May 21, 2024

Insufficient new directors

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Approves Management Appointments

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.33 in 3Q 2023)

Now 20% overvalued

Investor sentiment improves as stock rises 17%

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q3, 2024 Results on Oct 28, 2024

Now 27% overvalued after recent price rise

There Is A Reason Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) Price Is Undemanding

New major risk - Financial data availability

Second quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.34 in 2Q 2023)

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report First Half, 2024 Results on Aug 28, 2024

Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Shareholders Will Receive A Bigger Dividend Than Last Year

Dividend increased to CN¥0.22

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Announces Final Dividend on A Shares for the Year 2023, Payable on 03 June 2024

We Think That There Are Some Issues For Shaanxi Panlong Pharmaceutical Group Limited By Share (SZSE:002864) Beyond Its Promising Earnings

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd, Annual General Meeting, May 21, 2024

Now 21% overvalued

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Proposes Final Cash Dividend for the Year 2023

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q1, 2024 Results on Apr 26, 2024

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) announces an Equity Buyback for CNY 20 million worth of its shares.

Earnings Not Telling The Story For Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) After Shares Rise 32%

Investor sentiment deteriorates as stock falls 15%

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.33 (vs CN¥0.39 in 3Q 2022)

Investor sentiment improves as stock rises 18%

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q3, 2023 Results on Oct 30, 2023

Investor sentiment improves as stock rises 16%

Second quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.29 in 2Q 2022)

New minor risk - Dividend sustainability

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report First Half, 2023 Results on Aug 24, 2023

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd. Approves Cash Dividend for 2022

Insufficient new directors

First quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.23 in 1Q 2022)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 15%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd announced that it expects to receive CNY 302 million in funding

Third quarter 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 3Q 2021)

Now 20% undervalued after recent price drop

Investor sentiment improved over the past week

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Approves Management Appointments

Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.29 in 2Q 2021)

Investor sentiment improved over the past week

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Approves 2021 Profit Distribution Plan

Investor sentiment improved over the past week

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Proposes Final Cash Dividend for 2021

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.35 (vs CN¥0.39 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.27 in 2Q 2020)

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd. Announces Cash Dividend for the Year 2020, Payable on May 31, 2021

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Approves Cash Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.92 (vs CN¥0.83 in FY 2019)

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Fiscal Year 2020 Results on Apr 13, 2021

New 90-day low: CN¥22.24

New 90-day low: CN¥23.85

New 90-day low: CN¥25.17

Third quarter earnings released

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥25.52

New 90-day low - CN¥27.25

Earnings released

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report First Half, 2020 Results on Aug 25, 2020

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd